🇺🇸 FDA
Patent

US 7834024

Compositions and methods for inhibition of the JAK pathway

granted A61KA61K31/506A61K31/5375

Quick answer

US patent 7834024 (Compositions and methods for inhibition of the JAK pathway) held by Rigel Pharmaceuticals, Inc. expires Mon Nov 11 2030 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Rigel Pharmaceuticals, Inc.
Grant date
Tue Nov 16 2010 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Nov 11 2030 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
6
CPC classes
A61K, A61K31/506, A61K31/5375, A61K31/538, A61K31/5383